Marieke van Son

30 CHAPTER 2 salvage EBRT to the prostate bed (n=72) or EBRT+ADT (n=9). Among FT patients, 17 had a second focal re-do, 29 had salvage whole-gland radiotherapy (EBRT or I-125 brachytherapy), 4 had salvage whole-gland HIFU and 21 had salvage prostatectomy. Mortality was higher in the EBRT group (5.9%) than the LRP (2.8%) and FT (1.9%) groups. Follow-up time ranged from median 41 months (EBRT) to 62 months (focal) to 77 months (LRP). Table 1 – Treatment characteristics and outcomes Median (IQR) or number (%) Missing (%) EBRT (n=440) Neoadjuvant ADT 418 (95%) 5 (1.1%) Treatment protocol 60Gy in 20# 70Gy in 35# 72Gy in 32# 74Gy in 37# Other 101 (23%) 9 (2%) 80 (18.2%) 243 (55.2%) 7 (1.6%) BED (Gy) 173 (173 – 180) EQD 2 (Gy) 74 (74 – 77) Treatment failure 31 (7%) Salvage treatment 2 (0.4%) Metastases 7 (1.6%) Systemic treatment 10 (2.3%) Watchful waiting 17 (3.9%) Death 26 (5.9%) Follow-up time (months) 41 (21 – 61) LRP (n=390) Neoadjuvant ADT 17 (4.4%) 2 (0.5%) Adjuvant treatment EBRT 28 (7.2%) EBRT+ADT 12 (3.1%) Treatment failure 93 (23.8%) Salvage treatment 81 (20.8%) Metastases 8 (2%) Systemic treatment 19 (4.9%) Watchful waiting 2 (0.5%) Death 11 (2.8%) Follow-up time (months) 77 (45 – 102)